Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Bintrafusp alfa (M7824) is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|M7824||Bintrafusp alfa|MSB0011359C||Immune Checkpoint Inhibitor 95 PD-L1/PD-1 antibody 63 TGFBR2 Antibody 2||Bintrafusp alfa (M7824) is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||biliary tract cancer||not applicable||M7824||Phase I||Actionable||In a Phase I trial, Bintrafusp alfa (M7824) treatment in patients with advanced biliary tract cancer resulted in an objective response rate of 20% (6/30), with an additional six patients demonstrating stable disease, and median progression-free survival of 2.5 months, and median overall survival of 12.7 months (PMID: 32461347; NCT02699515).||32461347|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03620201||Phase I||M7824||M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)||Recruiting|
|NCT03631706||Phase II||M7824 Pembrolizumab||M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)||Recruiting|
|NCT04247282||Phase Ib/II||M7824 ETBX-011 + ETBX-051 + ETBX-061 + M7824 ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + M7824||Anti-PD-L1/TGF- <= Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for p16-Negative Resectable Head and Neck Squamous Cell Carcinoma||Recruiting|
|NCT04246489||Phase II||M7824||Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer||Recruiting|
|NCT04220775||Phase Ib/II||M7824||M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer||Recruiting|
|NCT04417660||Phase II||M7824||Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma||Not yet recruiting|
|NCT03436563||Phase Ib/II||M7824||M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer||Recruiting|
|NCT03427411||Phase II||M7824||Phase II Trial of M7824 in Subjects With HPV Positive Malignancies||Recruiting|
|NCT03833661||Phase II||M7824||M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)||Active, not recruiting|
|NCT03840902||Phase II||Carboplatin + Paclitaxel M7824 Cisplatin + Etoposide Durvalumab Cisplatin + Etoposide + M7824 Carboplatin + M7824 + Paclitaxel Cisplatin + M7824 + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium||M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)||Recruiting|
|NCT03524170||Phase I||M7824||RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer||Recruiting|
|NCT03554473||Phase Ib/II||M7824 + Topotecan M7824 + Temozolomide M7824||M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers||Recruiting|
|NCT03707587||Phase II||M7824||M7824 in People With Recurrent Respiratory Papillomatosis||Active, not recruiting|
|NCT02517398||Phase I||M7824||MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors||Active, not recruiting|